blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

Italy joins the Federated Register

Click here for more information on the Federated Register.

2025-06-12

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register User Manual
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3134120

EP3134120 - COMPOSITIONS AND METHODS FOR TREATING CYTOKINE-RELATED DISORDERS [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  20.03.2026
Database last updated on 08.04.2026
FormerThe patent has been granted
Status updated on  22.12.2023
FormerGrant of patent is intended
Status updated on  12.10.2023
FormerExamination is in progress
Status updated on  25.06.2019
FormerRequest for examination was made
Status updated on  27.01.2017
FormerThe international publication has been made
Status updated on  18.11.2016
Most recent event   Tooltip20.03.2026Revocation of patentpublished on 22.04.2026 [2026/17]
Applicant(s)For all designated states
The Children's Hospital of Philadelphia
3401 Civic Center Boulevard
Philadelphia, PA 19104 / US
For all designated states
The Trustees of The University of Pennsylvania
3160 Chestnut Street, Suite 200
Philadelphia, PA 19104 / US
[2024/01]
Former [2017/50]For all designated states
The Children's Hospital of Philadelphia
3401 Civic Center Boulevard
Philadelphia, PA 19104 / US
For all designated states
The Trustees of The University of Pennsylvania
3160 Market Street, Suite 200
Philadelphia, PA 19104 / US
Former [2017/09]For all designated states
The Children's Hospital of Philadelphia
34th and Civic Center Boulevard
Philadelphia, PA 19104 / US
For all designated states
The Trustees of The University of Pennsylvania
3160 Market Street, Suite 200
Philadelphia, PA 19104 / US
Inventor(s)01 / BEHRENS, Edward M.
111 Shady Grove Way
West Chester, PA 19382 / US
02 / ROOD, Julia E.
332 South 16th Street
Apt 3F
Philadelphia, PA 19102 / US
03 / KAMBAYASHI, Taku
2212 Swedesford Road
Malvern, PA 19355 / US
 [2017/09]
Representative(s)Potter Clarkson
Chapel Quarter
Mount Street
Nottingham NG1 6HQ / GB
[2024/04]
Former [2017/09]Potter Clarkson LLP
The Belgrave Centre
Talbot Street
Nottingham NG1 5GG / GB
Application number, filing date15782489.721.04.2015
[2017/09]
WO2015US26840
Priority number, dateUS201461982026P21.04.2014         Original published format: US 201461982026 P
US201461993495P15.05.2014         Original published format: US 201461993495 P
US201562146684P13.04.2015         Original published format: US 201562146684 P
[2017/09]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015164354
Date:29.10.2015
Language:EN
[2015/43]
Type: A1 Application with search report 
No.:EP3134120
Date:01.03.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 29.10.2015 takes the place of the publication of the European patent application.
[2017/09]
Type: B1 Patent specification 
No.:EP3134120
Date:24.01.2024
Language:EN
[2024/04]
Search report(s)International search report - published on:US29.10.2015
(Supplementary) European search report - dispatched on:EP02.08.2017
ClassificationIPC:A61K39/395, C07K14/54
[2017/09]
CPC:
C07K16/2866 (EP,US); A61K38/1793 (EP,US); A61K39/3955 (EP,US);
C07K14/54 (EP,US); C07K14/7155 (EP,US); A61K2039/505 (US);
C07K2317/72 (EP,US); C07K2317/76 (US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/09]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUR BEHANDLUNG VON ERKRANKUNGEN IM ZUSAMMENHANG MIT CYTOKIN[2017/09]
English:COMPOSITIONS AND METHODS FOR TREATING CYTOKINE-RELATED DISORDERS[2017/09]
French:COMPOSITIONS ET MÉTHODES POUR LE TRAITEMENT DE TROUBLES LIÉS AUX CYTOKINES[2017/09]
Entry into regional phase17.11.2016National basic fee paid 
17.11.2016Search fee paid 
17.11.2016Designation fee(s) paid 
17.11.2016Examination fee paid 
Examination procedure17.11.2016Examination requested  [2017/09]
17.11.2016Date on which the examining division has become responsible
27.02.2018Amendment by applicant (claims and/or description)
28.06.2019Despatch of a communication from the examining division (Time limit: M06)
18.12.2019Reply to a communication from the examining division
10.01.2020Despatch of a communication from the examining division (Time limit: M02)
02.03.2020Reply to a communication from the examining division
14.08.2020Observations by third parties
17.12.2020Despatch of a communication from the examining division (Time limit: M10)
25.10.2021Reply to a communication from the examining division
04.02.2022Despatch of a communication from the examining division (Time limit: M08)
22.09.2022Reply to a communication from the examining division
17.10.2022Observations by third parties
27.01.2023Despatch of a communication from the examining division (Time limit: M06)
22.06.2023Reply to a communication from the examining division
13.10.2023Communication of intention to grant the patent
19.12.2023Fee for grant paid
19.12.2023Fee for publishing/printing paid
19.12.2023Receipt of the translation of the claim(s)
Opposition(s)Opponent(s)01  23.10.2024  24.10.2024  ADMISSIBLE
SANOFI
46 avenue de la Grande Armeé
75017 Paris / FR
Opponent's representative
Zwicker, Jörk, et al, et al
ZSP Patentanwälte PartG mbB
Hansastraße 32
80686 München / DE
 [2024/48]
07.11.2024Invitation to proprietor to file observations on the notice of opposition
12.12.2025Legal effect of revocation of patent [2026/17]
12.12.2025Despatch of communication that the patent will be revoked
Fees paidRenewal fee
10.04.2017Renewal fee patent year 03
11.04.2018Renewal fee patent year 04
15.04.2019Renewal fee patent year 05
31.03.2020Renewal fee patent year 06
15.04.2021Renewal fee patent year 07
16.03.2022Renewal fee patent year 08
14.03.2023Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipCY21.04.2015
HU21.04.2015
AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SI24.01.2024
SK24.01.2024
SM24.01.2024
IE21.04.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
BE30.04.2024
CH30.04.2024
IS24.05.2024
PT24.05.2024
[2025/41]
Former [2025/37]CY21.04.2015
AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SI24.01.2024
SK24.01.2024
SM24.01.2024
IE21.04.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
BE30.04.2024
CH30.04.2024
IS24.05.2024
PT24.05.2024
Former [2025/22]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SI24.01.2024
SK24.01.2024
SM24.01.2024
IE21.04.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
BE30.04.2024
CH30.04.2024
IS24.05.2024
PT24.05.2024
Former [2025/11]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
BE30.04.2024
CH30.04.2024
IS24.05.2024
PT24.05.2024
Former [2025/08]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
BE30.04.2024
IS24.05.2024
PT24.05.2024
Former [2025/04]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
LU21.04.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2025/02]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
IT24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/52]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
MC24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/49]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
RO24.01.2024
SE24.01.2024
SK24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/48]AT24.01.2024
BG24.01.2024
CZ24.01.2024
DK24.01.2024
EE24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/47]AT24.01.2024
BG24.01.2024
DK24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
SM24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/37]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
SE24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/36]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
LV24.01.2024
NL24.01.2024
PL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
PT24.05.2024
Former [2024/35]AT24.01.2024
BG24.01.2024
ES24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
NL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
Former [2024/34]BG24.01.2024
FI24.01.2024
HR24.01.2024
LT24.01.2024
NL24.01.2024
NO24.04.2024
RS24.04.2024
GR25.04.2024
IS24.05.2024
Former [2024/33]LT24.01.2024
NL24.01.2024
NO24.04.2024
IS24.05.2024
Former [2024/32]NL24.01.2024
IS24.05.2024
Former [2024/31]NL24.01.2024
Documents cited:Search[PI]   JULIA ROOD ET AL: "Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis", 78TH ANNUAL MEETING OF THE AMERICAN-COLLEGE-OF-RHEUMATOLOGY (ACR) / 49TH MEETING OF THE ASSOCIATION-; BOSTON, MA, USA; NOVEMBER 14 -19, 2014, vol. 66, 14 November 2014 (2014-11-14), pages S835 - S836, XP055393906 * 633 to 634 *
 [A]   P. KREBS ET AL: "Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice", BLOOD, vol. 117, no. 24, 16 June 2011 (2011-06-16), pages 6582 - 6588, XP055393351, ISSN: 0006-4971, DOI: 10.1182/blood-2011-01-329607

DOI:   http://dx.doi.org/10.1182/blood-2011-01-329607
 [A]   SCOTT W. CANNA ET AL: "Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic Syndromes", PEDIATRIC CLINICS OF NORTH AMERICA., vol. 59, no. 2, 1 April 2012 (2012-04-01), GB, pages 329 - 344, XP055393343, ISSN: 0031-3955, DOI: 10.1016/j.pcl.2012.03.002

DOI:   http://dx.doi.org/10.1016/j.pcl.2012.03.002
 [A]   LUKE O'NEILL: "The interleukin-1 receptor/ Toll-like receptor superfamily: 10 years of progress", IMMUNOLOGICAL REVIEWS, vol. 226, 1 December 2008 (2008-12-01), pages 10 - 18, XP055393676 * 245 to 253 *

DOI:   http://dx.doi.org/10.1111/j.1600-065X.2008.00701.x
   JULIA E ROOD ET AL: "ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice", 30 October 2015 (2015-10-30), pages 6582 - 6588, XP055393347, Retrieved from the Internet [retrieved on 20170724], DOI: 10.1182/blood-2015-07-

DOI:   http://dx.doi.org/10.1182/blood-2015-07-
International search[XY] US2010260770  (COYLE ANTHONY et al.) [X] 1-3 * Abstract, para [0001]-[0004], [00141,[0028]-[0046],[0034],[0120],[0133]-[0134],[0185] *[Y] 4/3, 7-8
 [Y] WO2014011984  (UNIV PENNSYLVANIA et al.) [Y] 6-8 * Abstract, pg 3, In 10-14; pg 32-33, In 25-27 *
 [XY]   HONG ET AL.: "Measurement of Interleukin-33 ( IL -33) and IL -33 Receptors (sST2 and ST2L) in Patients with Rheumatoid Arthritis.", J KOREAN MED SCI, vol. 26, no. 9, September 2011 (2011-09-01), pages 1132 - 1139, XP002712942, DOI: doi:10.3346/jkms.2011.26.9.1132 [X] 1-2, 4/(1-2) * . Especially Abstract, pg 1133, col 1, para 1; pg 1132, col 1, para 2 to col 2, para 1 *[Y] 4/3

DOI:   http://dx.doi.org/10.3346/jkms.2011.26.9.1132
 [XY]   PALMER ET AL.: "Inhibition of Interleukin-33 Signaling Attenuates the Severity of Experimental Arthritis", ARTHRITIS & RHEUMATISM, vol. 60, no. 3, March 2009 (2009-03-01), pages 738 - 749, XP055016952, ISSN: 0004-3591 [X] 1, 4/1 * . Especially Abstract; pg 745, col 2, Figure 5 *[Y] 5-8

DOI:   http://dx.doi.org/10.1002/art.24305
 [Y]   BEHRENS ET AL.: "Interleukin 1 receptor antagonist to treat cytophagic histiocytic panniculitis wil secondary hemophagocytic lymphohistiocytosis", THE JOURNAL OF RHEUMATOLOGY, vol. 33, no. 10, October 2006 (2006-10-01), pages 2081 - 2084, XP008185224 [Y] 5 * . Especially Abstract; pg 745, col 1, para 1 *
by applicantUS7087396
 US7452980
 US8444987
 WO2013165894
 WO9934217
 WO2013173761
 US2013287777
 US2013336980
 US2014004107
 US2014271658
 WO2014152195
 WO2014164959
   STEPP ET AL., SCIENCE, vol. 286, no. 5446, 1999, pages 1957 - 1959
   BRISSE ET AL., CYTOKINE GROWTH FACTOR REV., 2014
   JANKA ET AL., BLOOD REV., vol. 28, no. 4, 2014, pages 135 - 142
   JORDAN ET AL., BLOOD, vol. 104, no. 3, 2004, pages 735 - 743
   LYKENS ET AL., BLOODL, vol. 18, no. 3, 2011, pages 618 - 626
   MATLOUBIAN ET AL., J. VIROL., vol. 73, no. 3, 1999, pages 2527 - 2536
   TERRELL ET AL., BLOOD, vol. 121, no. 26, 2013, pages 5184 - 5191
   LYKENS ET AL., BLOOD, vol. 118, no. 24, 2011, pages 6582 - 6588
   JESSEN ET AL., FRONT. IMMUNOL., vol. 4, 2013, pages 448
   BONILLA ET AL., SCIENCE, vol. 335, no. 6071, 2012, pages 984 - 989
   PORTER ET AL., N. ENGL. J. MED., vol. 365, 2011, pages 725 - 33
   GRUPP ET AL., N. ENGL. J. MED., vol. 368, 2013, pages 1509 - 18
   IWAHANA ET AL., EUR. J. BIOCHEM., vol. 264, 1999, pages 397 - 406
   PALMER ET AL., ARTHRITIS RHEUMAT., vol. 60, 2009, pages 738 - 749
   HAYAKAWA ET AL., J. BIOL. CHEM., vol. 282, 2007, pages 26369 - 26380
   KAWE ET AL., J. BIOL. CHEM., vol. 281, 2006, pages 40252 - 40263
   TERSKIKH ET AL., PNAS, vol. 94, 1997, pages 1663 - 1668
   ADACHI ET AL., IMMUNITY, vol. 9, no. 1, 2000, pages 143 - 150
   AHMED ET AL., J. EXP. MED., vol. 160, no. 2, 1984, pages 521 - 540
   PALMER ET AL., ARTHRITIS RHEUMATISM, vol. 60, no. 3, 2009, pages 738 - 749
   LEVY R.: "Using R formulae to test for main effects in the presence of higher-order interactions", ARXIV:STAT.ME/1405.2094V1, 2014
   KAKKAR ET AL., J. BIOL. CHEM., vol. 287, no. 9, 2012, pages 6941 - 6948
   MOUSSION ET AL., PLOS ONE, vol. 3, no. 10, 2008, pages e3331
   PICHERY ET AL., J. IMMUNOL., vol. 188, no. 7, 2012, pages 3488 - 3495
   SCHMITZ ET AL., IMMUNITY, vol. 23, no. 5, 2005, pages 479 - 490
   CHACKERIAN ET AL., J. IMMUNOL., vol. 179, no. 4, 2007, pages 2551 - 2555
   MIRCHANDANI ET AL., TRENDS IMMUNOL., vol. 33, no. 8, 2012, pages 389 - 396
   LUTHI ET AL., IMMUNITY, vol. 31, no. 1, 2009, pages 84 - 98
   CAYROL ET AL., PNAS, vol. 106, no. 22, 2009, pages 9021 - 9026
   YANG ET AL., EUR. J. IMMUNOL., vol. 41, no. 11, 2011, pages 3351 - 3360
   JAESCHKE ET AL., TOXICOLOG. SCI., vol. 65, no. 2, 2002, pages 166 - 176
   BOURGEOIS ET AL., EUR. J. IMMUNOL., vol. 39, no. 4, 2009, pages 1046 - 1055
   BROWNE ET AL., CURR. OPIN. ALLERGY CLIN. IMMUNOL., vol. 10, no. 6, 2010, pages 534 - 541
   SUSAN ET AL., CYTOKINE GROWTH FACTOR REV., vol. 11, no. 4, 2000, pages 321333
   TESI ET AL., J. ALLERGY CLINICAL IMMUNOL., 2015
   KAGI ET AL., CURR. OPIN. IMMUNOL., vol. 8, no. 4, 1996, pages 472 - 477
   KOUZAKI ET AL., J. IMMUNOL., vol. 186, no. 7, 2011, pages 4375 - 4387
   GARLANDA ET AL., IMMUNITY, vol. 39, no. 6, 2013, pages 1003 - 1018
   OBOKI ET AL., PNAS, vol. 107, no. 43, 2010, pages 18581 - 18586
   ZHANG ET AL., PLOS, vol. 9, no. 2, 2015, pages e0003514
otherUS201461982026
 US201461993495
 US201562146684
   ROOD ET AL.: "Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis", 2014 ACR/ARHP ANNUAL MEETING, abstract 1899, 2014, XP055393906 [Y] 5 * . Especially Abstract; pg 745, col 1, para 1 *
OppositionWO2005079844
 WO2014011984
   MARTINE SZYPER-KRAVITZ NULL: "The Hemophagocytic Syndrome/Macrophage Activation Syndrome: A Final Common Pathway of a Cytokine Storm", ISRAEL MEDICAL ASSOCIATION JOURNAL (IMAJ), vol. 11, October 2009 (2009-10-01), XP055763019 * 633 to 634 *
   ANONYMOUS: "Cytokine", WIKIPEDIA, 27 September 2024 (2024-09-27), XP093233817, Retrieved from the Internet
   ANONYMOUS: "Cytokine storm", WIKIPEDIA, 24 June 2024 (2024-06-24), XP093233820, Retrieved from the Internet
   JANKA, G.E.: "Hemophagocytic syndromes", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 21, no. 5, 10 August 2007 (2007-08-10), AMSTERDAM, NL , pages 245 - 253, XP022187287, ISSN: 0268-960X, DOI: 10.1016/j.blre.2007.05.001 * 245 to 253 *

DOI:   http://dx.doi.org/10.1016/j.blre.2007.05.001
   JANKA, G.: "Hemophagocytic Lymphohistiocytosis: When the Immune System Runs Amok [Hmophagozytierende Lymphohistiozytose: Wenn das Immunsystem Amok luft]", KLINISCHE PAEDIATRIE, GEORG THIEME VERLAG, DE, vol. 221, no. 5, 1 September 2009 (2009-09-01), DE , pages 278 - 285, XP009558856, ISSN: 1439-3824, DOI: 10.1055/s-0029-1237386

DOI:   http://dx.doi.org/10.1055/s-0029-1237386
   ATTERITANO M, DAVID A, BAGNATO G, BENINATI C, FRISINA A, IARIA C, CASCIO ANTONIO: "Haemophagocytic syndrome in rheumatic patients. A systematic review", EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, vol. 16, no. 10, 1 October 2012 (2012-10-01), pages 1414 - 1424, XP093233831 * 1414 to 1424 *
   ARONSON IRIS K., WOROBEC SOPHIE M.: "Cytophagic histiocytic panniculitis and hemophagocytic lymphohistiocytosis: an overview ", DERMATOLOGIC THERAPY, WILEY-BLACKWELL PUBLISHING, INC., US, vol. 23, no. 4, 1 July 2010 (2010-07-01), US , pages 389 - 402, XP093233834, ISSN: 1396-0296, DOI: 10.1111/j.1529-8019.2010.01339.x * 389 to 402 *
   TANG YONG-MIN, XU XIAO-JUN: "Advances in Hemophagocytic Lymphohistiocytosis: Pathogenesis, Early Diagnosis/Differential Diagnosis, and Treatment", THE SCIENTIFIC WORLD JOURNAL, THE SCIENTIFICWORLD LTD, GB, NL, vol. 11, 1 January 2011 (2011-01-01), GB, NL , pages 697 - 708, XP093233837, ISSN: 1537-744X, DOI: 10.1100/tsw.2011.62 * 697 to 708 *
   RAHUL KAKKAR ET AL.: "The IL-33/ST2 pathway: therapeutic target and novel biomarker", NAT REV DRUG DISCOV., vol. 7, October 2008 (2008-10-01), XP002530680, DOI: 10.1038/NRD2660 * 827 to 840 *

DOI:   http://dx.doi.org/10.1038/NRD2660
   ISHIKAWA SAYAKA, SHIMIZU MASAKI, UENO KAZUYUKI, SUGIMOTO NAOTOSHI, YACHIE AKIHIRO: "Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 62, no. 2, 1 May 2013 (2013-05-01), US , pages 272 - 277, XP093233839, ISSN: 1043-4666, DOI: 10.1016/j.cyto.2013.03.007 * 272 to 277 *
   PALMER, G. ; LIPSKY, B.P. ; SMITHGALL, M.D. ; MEININGER, D. ; SIU, S. ; TALABOT-AYER, D. ; GABAY, C. ; SMITH, D.E.: "The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US, vol. 42, no. 3, 1 June 2008 (2008-06-01), US , pages 358 - 364, XP022696634, ISSN: 1043-4666, DOI: 10.1016/j.cyto.2008.03.008 * 358 to 364 *

DOI:   http://dx.doi.org/10.1016/j.cyto.2008.03.008
   JANKA GRITTA E., LEHMBERG KAI: "Hemophagocytic syndromes An update", BLOOD REVIEWS, CHURCHILL LIVINGSTONE, AMSTERDAM, NL, vol. 28, no. 4, 1 July 2014 (2014-07-01), AMSTERDAM, NL , pages 135 - 142, XP093233848, ISSN: 0268-960X, DOI: 10.1016/j.blre.2014.03.002 * 135 to 142 *
   SCOTT W. CANNA, EDWARD M. BEHRENS: "Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic Syndromes", PEDIATRIC CLINICS OF NORTH AMERICA., SAUNDERS CO., LONDON., GB, vol. 59, no. 2, 1 April 2012 (2012-04-01), GB , pages 329 - 344, XP055393343, ISSN: 0031-3955, DOI: 10.1016/j.pcl.2012.03.002 * 329 to 344 *

DOI:   http://dx.doi.org/10.1016/j.pcl.2012.03.002
   GROM A.A., M. PASSO: " Macrophage activation syndrome in systemic juvenile rheumatoid arthritis", J PEDIATR ., vol. 129, no. 5, 1 November 1996 (1996-11-01), pages 630 - 632, XP093233853, DOI: 10.1016/s0022-3476(96)70140-3 * 630 to 632 *
   CECILIA GARLANDA NULL: "THE INTERLEUKIN-1 FAMILY: BACK TO THE FUTURE", IMMUNITY, vol. 39, 12 December 2013 (2013-12-12), XP055160331, DOI: 10.1016/j.immuni.2013.11.010 * 1003 to 1018 *

DOI:   http://dx.doi.org/10.1016/j.immuni.2013.11.010
   TRISTANO ANTONIO G.: "Macrophage activation syndrome: A frequent but under-diagnosed complication associated with rheumatic diseases", MEDICAL SCIENCE MONITOR, WARSAW, POLAND : MEDICAL SCIENCE INTERNATIONAL, PL, vol. 14, no. 3, 1 March 2008 (2008-03-01), PL , pages RA27 - RA36, XP093233856, ISSN: 1234-1010 * RA27 to RA36 *
   DINARELLO CHARLES A: "Proinflammatory Cytokines", CHEST, vol. 118, no. 2, 1 August 2000 (2000-08-01), pages 503 - 508, XP093233862, DOI: 10.1378/chest.118.2.503 * 503 to 508 *
   T. HORIUCHI, MITOMA H., HARASHIMA S.-I., TSUKAMOTO H., SHIMODA T.: "Transmembrane TNF-alpha: structure, function and interaction with anti-TNF agents", RHEUMATOLOGY, OXFORD UNIVERSITY PRESS, vol. 49, no. 7, 1 July 2010 (2010-07-01), pages 1215 - 1228, XP055077475, ISSN: 14620324, DOI: 10.1093/rheumatology/keq031 * 1215 to 1228 *

DOI:   http://dx.doi.org/10.1093/rheumatology/keq031
   CRON R.Q., M. ZHANG: "OP0017Blurring of the Distinction Between Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome", ORAL PRESENTATIONS - PATHOGENETIC INSIGHTS IN AUTOIMMUNITY FROM GENETIC DISEASES, BMJ PUBLISHING GROUP LTD AND EUROPEAN LEAGUE AGAINST RHEUMATISM, vol. 72, no. Suppl 3, 12 June 2013 (2013-06-12), pages A53 - A54, XP093233871, DOI: 10.1136/annrheumdis-2013-eular.220
   M. B. JORDAN, C. E. ALLEN, S. WEITZMAN, A. H. FILIPOVICH, K. L. MCCLAIN: "How I treat hemophagocytic lymphohistiocytosis", BLOOD, ISSUE 832, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 118, no. 15, 13 October 2011 (2011-10-13), US , pages 4041 - 4052, XP055288710, ISSN: 0006-4971, DOI: 10.1182/blood-2011-03-278127 * 4041 to 4052 *

DOI:   http://dx.doi.org/10.1182/blood-2011-03-278127
   "Autoimmune Disorders - Current Concepts and Advances from Bedside to Mechanistic Insights", 14 November 2011, INTECH , ISBN: 978-953-30-7653-9, article MACHACZKA MACIEJ, SYDOR WOJCIECH, RUCINSKA MAGORZATA, SZOSTEK MARTA, MUSIA JACEK: "Autoimmune-Associated Hemophagocytic Syndrome/Macrophage Activation Syndrome", XP093233881, DOI: 10.5772/20126 * 79 to 104 *
   COCA, A. ; BUNDY, K.W. ; MARSTON, B. ; HUGGINS, J. ; LOONEY, R.J.: "Macrophage activation syndrome: Serological markers and treatment with anti-thymocyte globulin", CLINICAL IMMUNOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 132, no. 1, 1 July 2009 (2009-07-01), AMSTERDAM, NL , pages 10 - 18, XP026152813, ISSN: 1521-6616, DOI: 10.1016/j.clim.2009.02.005 * 10 to 18 *

DOI:   http://dx.doi.org/10.1016/j.clim.2009.02.005
   GUPTA ABHA A., TYRRELL PASCAL, VALANI RAHIM, BENSELER SUSANNE, ABDELHALEEM MOHAMED, WEITZMAN SHEILA: "Experience With Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome at a Single Institution", JOURNAL OF PEDIATRIC HEMATOLOGY/ONCOLOGY, NEW YORK, US, vol. 31, no. 2, 1 February 2009 (2009-02-01), US , pages 81 - 84, XP093233886, ISSN: 1077-4114, DOI: 10.1097/MPH.0b013e3181923cb4 * 81 to 84 *
   BERNARD P LEUNG ET AL.: "A novel therapy of murine collagen-induced arthritis with soluble T1/ST2", JOURNAL OF IMMUNOLY, vol. 173, 2004, XP009167840, DOI: 10.4049/jimmunol.173.1.145 * 145 to 150 *

DOI:   http://dx.doi.org/10.4049/jimmunol.173.1.145
   JENNIFER KEARLEY ET AL.: "Resolution of allergic inflammation and airway hyperreactivity is dependent upon disruption of the T1/ST2-IL-33 pathway", AM J RESPIR CRIT CARE MED, vol. 179, 2009, XP002647399, DOI: 10.1164/rccm.200805-666OC * 772 to 781 *

DOI:   http://dx.doi.org/10.1164/rccm.200805-666OC
   KUROWSKA-STOLARSKA MARIOLA, STOLARSKI BARTOSZ, KEWIN PETER, MURPHY GRACE, CORRIGAN CHRISTOPHER J., YING SUN, PITMAN NICK, MIRCHAND: "IL-33 Amplifies the Polarization of Alternatively Activated Macrophages That Contribute to Airway Inflammation", JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO., vol. 183, no. 10, 15 November 2009 (2009-11-15), pages 6469 - 6477, XP093233887, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901575 * 6469 to 6477 *

DOI:   http://dx.doi.org/10.4049/jimmunol.0901575
   D29 - FRA U.S. FOOD AND DRUG ADMINISTRATION: "Ziv-Aflibercept", Retrieved from the Internet [retrieved on 20241003]
   MARTIN H COHEN ET AL.: "FDA Drug Approval Summary: Bevacizumab Plus FOLFOX4 asSecond-Line Treatment of Colorectal Cancer", THE ONCOLOGIST, vol. 12, 2007, XP002712135, DOI: 10.1634/theoncologist.12-3-356 * 356 to 361 *

DOI:   http://dx.doi.org/10.1634/theoncologist.12-3-356
   JIN GUANGXU, WONG STEPHEN T.C.: "Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 5, 1 May 2014 (2014-05-01), AMSTERDAM, NL , pages 637 - 644, XP093233891, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2013.11.005 * 637 to 644 *

DOI:   http://dx.doi.org/10.1016/j.drudis.2013.11.005
   GABY PALMER ET AL.: "Inhibition of interleukin-33 signaling attenuates the severity of experimental arthritis", ARTHRITIS & RHEUMATISM, vol. 60, 3 March 2009 (2009-03-03), XP055016952, DOI: 10.1002/art.24305 * 738 to 749 *

DOI:   http://dx.doi.org/10.1002/art.24305
   HENDERSON LAUREN A., CRON RANDY Q.: "Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Childhood Inflammatory Disorders: Diagnosis and Management", PAEDIATRIC DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 22, no. 1, 1 February 2020 (2020-02-01), NZ , pages 29 - 44, XP093233892, ISSN: 1174-5878, DOI: 10.1007/s40272-019-00367-1 * 29 to 44 *
   KEISUKE OBOKI, TATSUKUNI OHNO, NAOKI KAJIWARA, HIROHISA SAITO, SUSUMU NAKAE: "IL-33 and IL-33 Receptors in Host Defense and Diseases", ALLERGOLOGY INTERNATIONAL, BLACKWELL PUB., vol. 59, no. 2, 1 June 2010 (2010-06-01), pages 143 - 160, XP055016756, ISSN: 13238930, DOI: 10.2332/allergolint.10-RAI-0186 * 143 to 160 *

DOI:   http://dx.doi.org/10.2332/allergolint.10-RAI-0186
   HIROKO HAYAKAWA ET AL.: "Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation", THE JOURNAL OF BIOLOGICAL CHEMISTRY;, vol. 282, 7 September 2007 (2007-09-07), XP055030354, DOI: 10.1074/jbc.M704916200 * 26369 to 26380 *

DOI:   http://dx.doi.org/10.1074/jbc.M704916200
   BEHRENS EDWARD M., CANNA SCOTT W., SLADE KATHARINE, RAO SHEILA, KREIGER PORTIA A., PAESSLER MICHELE, KAMBAYASHI TAKU, KORETZKY GAR: "Repeated TLR9 stimulation results in macrophage activation syndromelike disease in mice", JOURNAL OF CLINICAL INVESTIGATION, AMERICAN SOCIETY FOR CLINICAL INVESTIGATION, vol. 121, no. 6, 1 June 2011 (2011-06-01), pages 2264 - 2277, XP093233896, ISSN: 0021-9738, DOI: 10.1172/JCI43157 * 2264 to 2277 *
   STRIPPOLI RAFFAELE, CARVELLO FRANCESCO, SCIANARO ROBERTA, DE PASQUALE LOREDANA, VIVARELLI MARINA, PETRINI STEFANIA, BRACCILAUDIER: "Amplification of the response to Tolllike receptor ligands by prolonged exposure to interleukin6 in mice: Implication for the pathogenesis of macrophage activation syndrome", ARTHRITIS & RHEUMATISM, WILEY INTERSCIENCE, US, vol. 64, no. 5, 1 May 2012 (2012-05-01), US , pages 1680 - 1688, XP093233898, ISSN: 0004-3591, DOI: 10.1002/art.33496 * 1680 to 1688 *
   SATO KEI, MISAWA NAOKO, NIE CHUANYI, SATOU YORIFUMI, IWAKIRI DAI, MATSUOKA MASAO, TAKAHASHI REI, KUZUSHIMA KIYOTAKA, ITO MAMORU, T: "A novel animal model of Epstein-Barr virusassociated hemophagocytic lymphohistiocytosis in humanized mice", BLOOD, ISSUE 832, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 117, no. 21, 26 May 2011 (2011-05-26), US , pages 5663 - 5673, XP093233900, ISSN: 0006-4971, DOI: 10.1182/blood-2010-09-305979 * 5663 to 5673 *

DOI:   http://dx.doi.org/10.1182/blood-2010-09-305979
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.